| Patent Number |
Title Of Patent |
Date Issued |
| 6759036 |
Fibrocyte-base vaccine formulations |
July 6, 2004 |
| There is disclosed a fibrocyte-based vaccine formulations made from isolated fibrocytes. There is further disclosed a method for establishing an immune response against a specific antigen by administering a fibrocyte-based vaccine formulation, such as one made by pulsing fibrocytes i |
| 6649797 |
Compounds and methods of use to treat infectious diseases |
November 18, 2003 |
| The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. |
| 6645493 |
Composition containing anti-MIF antibody |
November 11, 2003 |
| The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cy |
| 6596851 |
Inducible phosphofructokinase and the Warburg effect |
July 22, 2003 |
| There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of iPFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligon |
| 6538131 |
Synthetic process for highly functionalized carbocyclic polyols and substituted sugar analogs |
March 25, 2003 |
| Chemical processes for more efficient synthesis of carbocyclic polyols and substituted sugar analogs are disclosed, together with a novel class of cyclopentene polyol intermediate products and anhydro derivatives thereof. |
| 6492428 |
Compounds having MIF antagonist activity |
December 10, 2002 |
| There are disclosed methods of use and pharmaceutical compositions for two related genera of low molecular weight compounds comprising optionally substituted iminoquinone or orthoquinone ring systems. The compounds have MIF (macrophage migration inhibitory factor) antagonist activity and |
| 6440749 |
Method of treating certain indications associated with hyperglycemia |
August 27, 2002 |
| The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, |
| 6420188 |
Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
July 16, 2002 |
| The present invention encompasses assays to identify compounds that inhibit the enzymatic activity of MIF which catalyzes the tautomerization of MIF-substrates, such as D-dopachrome to DHICA. In general, the assay is conducted in vitro by adding, mixing or combining MIF and a suitable |
| 6413939 |
Inducible phosphofructokinase and the Warburg effect |
July 2, 2002 |
| There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of PFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligonu |
| 6380165 |
Immunological advanced glycation endproduct crosslink |
April 30, 2002 |
| There is disclosed a means for standardizing a kit that provides a means for measuring the formation of advanced glycosylation endproducts (AGEs). The present invention further provides a novel isolate AGE that is antigenic and useful for forming antibodies having utility in diagnostic |
| 6319894 |
Complexes and combinations of fetuin with therapeutic agents |
November 20, 2001 |
| There is disclosed a complex and a combination of the glycosylated polypeptide fetuin and a therapeutically active small molecule compound having a net positive charge at physiological pH. The presence of fetuin as a drug complex or in combination with the therapeutically active small |
| 6297253 |
Compounds and methods of use to treat infectious diseases |
October 2, 2001 |
| The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. |
| 6255046 |
Inducible phosphofructokinase and the warburg effect |
July 3, 2001 |
| There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of iPFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligon |
| 6248787 |
Guanylhydrazones and their use to treat inflammatory conditions |
June 19, 2001 |
| This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic gu |
| 6180676 |
Guanylhydrazones and their use to treat inflammatory conditions |
January 30, 2001 |
| This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic gu |
| 6174526 |
Blood-borne mesenchymal cells |
January 16, 2001 |
| The present invention relates to a population of blood borne mammalian cells that express a unique profile of surface markers that includes certain markers typical of connective tissue fibroblasts, and are referred to herein as "blood-borne mesenchymal cells." In particular, it relates t |
| 6143728 |
Guanylhydrazones useful for treating diseases associated with T cell activation |
November 7, 2000 |
| There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds |
| 6117837 |
Inhibiting proinflammatory cytokine production |
September 12, 2000 |
| There is disclosed a method for helping to prevent miscarriages during pregnancy, comprising administering an effective amount of a fetuin polypeptide. |
| 6110968 |
Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacc |
August 29, 2000 |
| Methods are provided for measuring the accumulation of advanced glycosylation endproducts (AGEs), and for lowering the accumulation of advanced glycosylation endproducts, which are predicated on the discovery that such AGEs and their precedent glycotoxins are present in tobacco and i |
| 6080407 |
Diagnostic assays for MIF |
June 27, 2000 |
| The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cy |
| 6054121 |
Modulation of immune responses in blood-borne mesenchymal cells |
April 25, 2000 |
| The present invention relates to a population of blood borne mammalian cells that express a unique profile of surface markers that includes certain markers typical of connective tissue fibroblasts, and are referred to herein as "blood-borne mesenchymal cells." In particular, it relates t |
| 6030615 |
Combination method for treating diseases caused by cytokine-mediated toxicity |
February 29, 2000 |
| There is disclosed a method for treating an individual having a disease caused by cytokine-mediated toxicity comprising administering to the individual an effective amount of (a) an antibody that binds to an MIF polypeptide, wherein the MIF polypeptide has a molecular weight of about |
| 6025401 |
Method and agents for inhibiting protein aging |
February 15, 2000 |
| The present invention relates to compositions and methods for inhibiting the aging of amino-containing amino acid, peptides, proteins and biomolecules. Accordingly, a composition is disclosed which comprises an agent or compound capable of reacting with the glycosyl-amino moiety of t |
| 6022900 |
Guanylhydrazones and their use to treat inflammatory conditions |
February 8, 2000 |
| This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic gu |
| 6019979 |
Anti-viral treatment with pertussis toxin B oligomer |
February 1, 2000 |
| There is disclosed a method for anti-viral therapy treatment with the Pertussis toxin beta subunit oligomer, wherein the oligomer is composed of from two to ten subunits of PTX selected from the group consisting of S2, S3, S4, S5, and combinations thereof. |
| 6011005 |
Prevention of pregnancy miscarriages |
January 4, 2000 |
| There is disclosed a method for helping to prevent miscarriages during pregnancy, comprising administering an effective amount of a fetuin polypeptide. |
| 6008255 |
Guanylhydrazones and their use to treat inflammatory conditions |
December 28, 1999 |
| This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic gu |
| 5962245 |
Methods for detecting the presence of advanced glycosylation endproducts |
October 5, 1999 |
| The present invention is directed to methods for detecting the presence of advanced glycosylation endproducts using the unexpected discovery that certain antibacterial proteins, in particular lysozyme and lactoferrin, bind to advanced glycosylation endproducts (AGEs) with high affinity, |
| 5935927 |
Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advance |
August 10, 1999 |
| The present invention relates generally to methods and compositions for treating amyloidogenic diseases such as Alzheimer's disease and the development of type II diabetes, in which deposition of amyloid in organs such as the brain and pancreas interfere with neurological function and |
| 5921248 |
Tobacco combination product filter |
July 13, 1999 |
| There are disclosed filters for tobacco combustion products that, when employed in conjunction with exposure to tobacco smoke, inhibit the accumulation of AGEs and AGE-like tobacco- and tobacco smoke-derived adducts in individuals exposed to tobacco smoke. There is further disclosed |
| 5891341 |
Compositions and devices for partitioning advanced glycosylation endproducts, and methods of the |
April 6, 1999 |
| The present invention is directed to compositions and devices based upon the unexpected discovery that certain antibacterial proteins, in particular lysozyme and lactoferrin, bind to advanced glycosylation endproducts (AGEs) with high affinity, and that this binding activity is subst |
| 5869534 |
Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods a |
February 9, 1999 |
| The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glyc |
| 5861238 |
Methods for partitioning advanced glycosylation endproducts |
January 19, 1999 |
| The present invention is directed to methods for partitioning advanced glycosylation endproducts out of a biological sample using the unexpected discovery that certain antibacterial proteins, in particular lysozyme and particular fragments thereof, bind to advanced glycosylation endprodu |
| 5859062 |
Guanylhydrazones and their use to treat inflammatory conditions |
January 12, 1999 |
| This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic gu |
| 5855882 |
Methods for inhibiting the cross-linking of advanced glycosylation endproducts |
January 5, 1999 |
| The present invention is directed to methods for inhibiting the cross-linking of advanced glycosylation endproducts in a subject suspected of having elevated levels of AGEs by using the unexpected discovery that certain antibacterial proteins, in particular lysozyme and particular fr |
| 5854289 |
Guanylhydrazones and their use to treat inflammatory conditions |
December 29, 1998 |
| This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic gu |
| 5854000 |
Methods for measurement predicated on the presence of advanced glycosylation endproducts in toba |
December 29, 1998 |
| Methods are disclosed for measuring the accumulation of advanced glycosylation endproducts (AGEs), which are predicated on the discovery that such AGEs are present in tobacco and its byproducts. More particularly, the methods focus on the observation that individuals who smoke or oth |
| 5853703 |
Preventing and reversing the formation of advanced glycosylation endproducts |
December 29, 1998 |
| The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, |
| 5850840 |
Methods for measurement and treatment predicated on the presence of advanced glycosylation endpr |
December 22, 1998 |
| Methods are provided for measuring the accumulation of advanced glycosylation endproducts (AGEs), and for lowering the accumulation of advanced glycosylation endproducts, which are predicated on the discovery that such AGEs and their precedent glycotoxins are present in tobacco and i |
| 5849794 |
Guanylhydrazones and their use to treat inflammatory conditions |
December 15, 1998 |
| This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic gu |
| 5849793 |
HIV matrix protein tyrosine position 29 pocket binders |
December 15, 1998 |
| There is disclosed a structural genus of compounds, defined according to coordinates in three-dimensional space, that binds amino moieties on neighboring lysine residues in a tyrosine residue 29 pocket of the matrix protein component of the HIV preintegration complex (PIC), thereby p |
| 5849307 |
Vaccine adjuvant |
December 15, 1998 |
| There is disclosed an adjuvant composition for potentiating the immunogenicity of an antigen, comprising water or an aqueous solution and hemozoin or .beta.-hematin. |
| 5846796 |
Blood-borne mesenchymal cells |
December 8, 1998 |
| The present invention relates to a population of blood borne mammalian cells that express a unique profile of surface markers that includes certain markers typical of connective tissue fibroblasts, and are referred to herein as "blood-borne mesenchymal cells." In particular, it relates t |
| 5840893 |
Compounds for treating infectious diseases |
November 24, 1998 |
| There is disclosed compound according to the formula: ##STR1## wherein A, independently,=CH.sub.3 or CH.sub.2 CH.sub.3, P=1 or 2; and ##STR2## wherein X=NH.sub.2, CH.sub.3 or CH.sub.2 CH.sub.3 ; X'=CH.sub.3 or CH.sub.2 CH.sub.3 ; Y=NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2 ; and Z= |
| 5840305 |
Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity |
November 24, 1998 |
| The present invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of HIV-infection using cyclophilin A and its corresponding human cellular binding partner or receptor as a target for intervention. The present invention relates to the use of exogen |
| 5811401 |
Advanced glycosylation endproducts and methods of use therefor |
September 22, 1998 |
| The present invention relates to advaced glycosylation endproducts formed by the reaction of arginine-lysine or lysine-arginine dipeptides, optionally as part of a larger protein or amino-containing-biomolecule, with reducing sugars. These AGEs can be used in various diagnostic and t |
| 5808068 |
HIV nuclear localization inhibitors |
September 15, 1998 |
| There is disclosed a genus of compounds that have anti-HIV infection therapeutic activity and inhibit nuclear localization of the HIV preintegration complex. |
| 5804446 |
Blood-borne mesenchymal cells |
September 8, 1998 |
| The present invention relates to a population of blood borne mammalian cells that express a unique profile of surface markers that includes certain markers typical of connective tissue fibroblasts, and are referred to herein as "blood-borne mesenchymal cells." In particular, it relates t |
| 5801200 |
Methods and materials for the diagnosis and treatment of conditions such as stroke |
September 1, 1998 |
| The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glyc |
| 5780615 |
Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods an |
July 14, 1998 |
| The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as ME-peptides, or a compound which forms advanced glyco |
